Logo.png
LEXEO Therapeutics Closes $100 Million Series B Financing to Advance Clinical Stage Gene Therapy Pipeline and Enhance Preclinical Footprint
September 09, 2021 06:00 ET | LEXEO Therapeutics
Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical...
Logo.png
LEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX1004 for the Treatment of CLN2 Batten Disease
July 28, 2021 08:30 ET | LEXEO Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced...
Logo.png
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases
July 21, 2021 08:30 ET | LEXEO Therapeutics
LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic...
Logo.png
LEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX2006 for the Treatment of Friedreich’s Ataxia
June 30, 2021 08:30 ET | LEXEO Therapeutics
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
Logo.png
LEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting
April 28, 2021 08:30 ET | LEXEO Therapeutics
Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases ...
Logo.png
LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 for the Treatment of APOE4 Associated Alzheimer’s Disease
April 20, 2021 08:30 ET | LEXEO Therapeutics
LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease Initial Phase 1 clinical data expected in 2H 2021 NEW YORK, April 20,...
Logo.png
LEXEO Therapeutics Strengthens Management Team with Key Appointments to Accelerate Development of Clinical-Stage Pipeline
April 06, 2021 08:30 ET | LEXEO Therapeutics
NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced the continued expansion of its management team with the appointments of two...
Logo.png
LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)
March 01, 2021 16:30 ET | LEXEO Therapeutics
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed...
Logo.png
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
January 07, 2021 07:30 ET | LEXEO Therapeutics
Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene...